Analyst Ratings For BTAI – BioXcel Therapeutics (NASDAQ:BTAI)
Today, Canaccord Genuity initiated coverage on BTAI – BioXcel Therapeutics (NASDAQ:BTAI) with a Buy with a price target of $21.00.
Some recent analyst ratings include
- 4/2/2018-Canaccord Genuity initiated coverage with a Buy rating.
- 4/2/2018-BMO Capital Markets initiated coverage with a Outperform rating.
- 4/2/2018-Barclays initiated coverage with a Overweight rating.
Recent Trading Activity for BTAI – BioXcel Therapeutics (NASDAQ:BTAI)
Shares of BTAI – BioXcel Therapeutics closed the previous trading session at with 10.5 shares trading hands.